Cystic Fibrosis
Enterprise Therapeutics Limited focuses its clinical research on cystic fibrosis, with interest in treatments designed for people living with this inherited respiratory disease. The funded work centers on inhaled therapies intended to address lung function and disease-related symptoms in pwCF.
- Cystic Fibrosis
- Respiratory Disease
- Inherited Disease
The sponsor’s clinical activity includes evaluation of inhaled therapeutic approaches aimed at improving pulmonary function, with attention to measures such as forced expiratory volume in 1 second and other markers relevant to airway health.
Inhaled Respiratory Therapies
Its research portfolio includes inhaled drug delivery for the treatment of chronic airway disease, reflecting an interest in medicines designed to act directly in the lungs. The clinical program examines repeat inhaled administration in the context of airway obstruction and respiratory symptom control.
- Inhaled Drug Delivery
- Airway Obstruction
- Lung-Directed Therapy
Research attention extends to the clinical performance of inhaled candidates in relation to safety, tolerability, and respiratory outcomes in people with cystic fibrosis.
Pulmonary Function Assessment
The sponsor’s trial activity places emphasis on lung function assessment as a key therapeutic endpoint, particularly using ppFEV1 to understand the impact of treatment on breathing capacity. This area is central to evaluating therapies for chronic pulmonary disease.
- ppFEV1
- Pulmonary Function
- Breathing Capacity
Clinical interest includes how repeated inhaled treatment may influence respiratory performance in a patient population with persistent airway disease.
Safety and Tolerability
Enterprise Therapeutics Limited also investigates the safety profile and tolerability of its respiratory candidate in people with cystic fibrosis. This includes monitoring how the treatment is received when delivered by inhalation over repeated use.
- Safety Profile
- Tolerability
- Repeat Inhaled Treatment
The sponsor’s research is aligned with the development of targeted pulmonary medicines for chronic genetic lung disease.
